StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a research note released on Tuesday morning. The firm issued a sell rating on the stock.
Separately, Needham & Company LLC decreased their price target on OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a research note on Tuesday, April 4th.
OncoCyte Trading Down 2.5 %
Shares of OCX opened at $0.21 on Tuesday. OncoCyte has a 52-week low of $0.20 and a 52-week high of $1.35. The business’s fifty day moving average is $0.26 and its 200-day moving average is $0.30.
Insider Buying and Selling
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new position in shares of OncoCyte in the 2nd quarter valued at about $25,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of OncoCyte in the 1st quarter valued at about $25,000. DCF Advisers LLC lifted its stake in shares of OncoCyte by 107.0% in the 1st quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after purchasing an additional 13,000 shares during the period. Balyasny Asset Management LLC lifted its stake in shares of OncoCyte by 389.9% in the 3rd quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock valued at $39,000 after purchasing an additional 42,091 shares during the period. Finally, LPL Financial LLC lifted its stake in shares of OncoCyte by 58.1% in the 2nd quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock valued at $98,000 after purchasing an additional 40,000 shares during the period. 81.20% of the stock is owned by institutional investors and hedge funds.
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services.
- Get a free copy of the StockNews.com research report on OncoCyte (OCX)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.